Frenova, a Fresenius Medical Care (FMC) company, supports sponsors and principal investigators conducting research specific to chronic kidney disease (CKD and ESRD) and it’s adjacent conditions, including rare diseases. We manage the world’s largest network of renal research assets, providing access to a global network of clinical trial resources including 350 research sites and 550 investigators. These resources, combined with our access to FMC’s data assets, provide unparalleled advantage to sponsors seeking to advance the science of renal therapies.
Scendea is a leading product development and regulatory consulting practice serving the pharmaceutical and biotechnology industry. Scendea was founded as a result of a management buyout of the product development and regulatory consulting function of a clinical research organisation. Our origin dates back over 20 years, with involvement in over 1,000 development programmes. Scendea has team members based in the UK, Ireland, the Netherlands and the US.
Scendea’s expert team deliver strategic and operational support in the fields of quality/CMC, non-clinical/toxicology, clinical/medical and regulatory to successfully guide products from early development to marketing approval. A combination of scientific excellence, industry experience and commercial awareness allow our expert team to solve complex issues associated with medicinal product development, aligned to jurisdiction-specific regulatory requirements.